Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
zelestrocel
- Development stage
- Unknown
- Lead developer
- Magellan
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Zelestrocel (formerly MAG200) is an allogeneic, donor-derived mesenchymal stem cell (MSC) therapy developed by Magellan Stem Cells for the treatment of osteoarthritis. Administered via intra-articular injection, the therapy is designed to modulate the inflammatory environment within the joint and promote tissue repair. The program has completed Phase I/IIa clinical evaluation and is transitioning into Phase III development, supported by Australian Medical Research Future Fund (MRFF) grant funding.
- Other names
- zelestrocelMAG200MAG-200MAG 200
Beyond the preview
Go deeper on zelestrocel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on zelestrocel.